Tin tức & Cập nhật
Lọc theo Chuyên ngành:
High-dose radiotherapy boosts biochemical control in Gleason 9–10 prostate cancer
In patients with clinically localized Gleason 9–10 prostate cancer, dose-escalated radiotherapy confers better biochemical disease-free survival and prostate cancer-specific mortality than conventional doses, a recent study has found.
High-dose radiotherapy boosts biochemical control in Gleason 9–10 prostate cancer
15 Jan 2022
Pola-R-CHP triumphs over R-CHOP in improving PFS in DLBCL
The combination of polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) demonstrated a significant improvement in progression-free survival (PFS) over the standard-of-care (SoC) regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), according to results of the phase III POLARIX study.
Pola-R-CHP triumphs over R-CHOP in improving PFS in DLBCL
14 Jan 2022
Long-term statin users at risk of colon cancer
Use of statins does not appear to be chemopreventive against colorectal cancer (CRC), and no significant association exists between total cholesterol level and CRC risk, a study has found. In addition, long-term statin use may increase the risk of colon cancer.
Long-term statin users at risk of colon cancer
13 Jan 2022
Fulvestrant-palbociclib combo pre-progression improves PFS in ESR1+ mBC
Switching to a fulvestrant-palbociclib regimen prior to disease progression after detection of elevated ESR1 mutations in the blood of patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) who were receiving aromatase inhibitors (AIs) plus palbociclib extended their progression-free survival (PFS), results of the phase III PADA-1 trial showed.